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ABSTRACT  
Objective: To assess whether fixation method and vitamin D supplementation impact the 
risk of patient important outcomes within 12 months of injury in non-geriatric femoral 
neck fracture patients. 
Design: Pilot factorial randomized controlled trial. 
Setting: 15 North American clinical sites. 
Participants: 91 adults aged 18-60 years with a femoral neck fractu e requiring surgical 
fixation. 
Intervention: Participants were randomized to a surgical intervention (sliding hip screw 
or cancellous screws) and a vitamin D intervention (vitamin D3 4,000 IU daily versus 
placebo for 6 months). 
Main Outcome Measurements: The primary clinical outcome was a composite of patient 
important complications (re-operation, femoral head osteonecrosis, severe femoral neck 
malunion, nonunion). Secondary outcomes included fracture healing complications and 
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Results: 86 participants with a mean age of 41 years were included. We found no 
statistically significant difference in the risk of patient important outcomes between the 
surgical treatment arms (hazard ratio (HR) 0.90, 95% CI 0.40-2.02, p=0.80) and vitamin 
D supplementation treatment arms (HR 0.96, 95% CI 0.42- 2.18, p=0.92). 
Conclusions: These pilot trial results continue to describe the results of current fixation 
implants, inform the challenges of improving outcomes in this fracture population, and 
may guide future vitamin D trials to improve healing outcomes in young fracture 
populations. Although the pilot trial was not adequately powered to detect treatment 
effects, publishing these results may facilitate future meta-analyses on this topic.   
Level of Evidence: Therapeutic Level II 
Keywords: clinical protocols; femoral neck fractures; fracture fixation, internal; vitamin D; randomized 
controlled trial 
INTRODUCTION  
Femoral neck fractures in non-geriatric adults represent a distinct and challenging hip 
fracture population.  The differences in physiology, injury characteristics, and activity 
level warrant a different treatment pathway compared to elderly fracture patients.1–3 
Internal fixation methods, using either cancellous screws (CS) or a sliding hip screw 
(SHS), are used to manage most femoral neck fractures in patients ≤60 years.3 Despite 
internal fixation being the standard of care for treating younger adults with femoral neck 
fractures, there is no conclusive clinical evidence to determine if the CS or the SHS is the 
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In addition to the lack of consensus for the optimal fixation device, it is plausible that 
non-surgical treatments could also improve fracture healing outcomes. Vitamin D is an 
essential nutrient for bone health and experimental animal studies suggest it may also 
play an important role in fracture healing.5–9 Numerous observational studies have 
reported that nearly 75% of healthy adult fracture patients between the ages of 18-50 
have vitamin D deficiency or insufficiency5,6 Moreover, circulating vitamin D levels have 
been reported to acutely decrease following a fractu e.6,7,10–13 Therefore, vitamin D 
supplementation for young femoral neck fracture patients may be an effective non-
surgical adjuvant therapy to improve healing outcomes.6,14,15  
Recognizing the controversies surrounding implant selection and the unknown effect of 
vitamin D supplementation for young femoral neck fracture patients, we conducted the 
Fixation using Alternative Implants for the Treatment of Hip Fractures (FAITH-2) pilot 
trial.  The primary clinical research objective of the FAITH-2 pilot trial was to determine 
whether fixation with a SHS and supplementation with v amin D independently lowered 
the risk of patient important complications during the 12-month post-injury follow-up 
period in young adults (ages 18-60) with femoral neck fractures. Details of the feasibility 
and vitamin D supplementation adherence of the FAITH-2 pilot trial are reported 
separately.16 Since these analyses demonstrated a multicenter definitiv  trial was not 
feasible, we present the clinical outcomes data for the pilot trial.  We considered all 
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MATERIALS AND METHODS 
Trial Design  
FAITH-2 was a pilot trial conducted to determine the feasibility of a definitive 2x2 
factorial design randomized controlled trial (RCT) comparing the two surgical implants 
plus vitamin D supplementation versus placebo for the treatment of femoral neck 
fractures in young adult patients (ages 18-60). A previously published protocol 
manuscript details the trial objectives and methods.2 The trial was registered with 
ClinicalTrials.gov, number NCT01908751, and it was pproved by the Hamilton 
Integrated Research Ethics Board (#13-807) and by all participating clinical sites’ 
research ethics boards/institutional review boards.  
 
Participants  
We randomized patients with a femoral neck fracture requiring fracture fixation across 15 
clinical centers in the USA and Canada. Eligible patients were adult men and women 
aged 18 to 60 years with a femoral neck fracture. All fracture patterns (subcapital, 
midcervical, or basicervical) amenable to both surgical treatments (SHS and CS) were 
eligible.  Patients with osteoporosis or other bone metabolism disorders were excluded. 
Ipsilateral femoral shaft fractures treated with retrograde nailing or plating were eligible 
for inclusion, as well as patients with multiple trauma.  
 
Surgical Procedures 
Participants allocated to the CS group received multiple cancellous screws with a 
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larger diameter partially threaded screw affixed to the proximal femur with a side-plate. 
Surgeons were permitted to use any fixed-angle plate construct which included a large 
diameter screw or blade that could slide within the plate. Surgeons were also allowed to 
use additional derotation screws and buttress plates.  
 
Procedures for Vitamin D Supplementation 
Vitamin D supplementation was administered upon hospital discharge or within two 
weeks of the participant’s femoral neck surgery, whichever came first. Participants 
allocated to the vitamin D group received a bottle of 2,000 IU vitamin D drops (Ddrops®, 
Ddrops Company) and were instructed to take two drops daily for six months, for a total 
daily dose of 4,000 IU. Participants in the placebo gr up received an identical bottle of 
placebo drops with no active ingredient.  
 
Follow-up Schedule  
Participant follow-up visits occurred post-operatively, and at 6 weeks, 3 months, 6 
months, 9 months, and 12 months post-fracture.  
 
Primary Clinical Outcome 
The primary clinical outcome for the pilot trial was a composite of patient important 
outcomes that occurred within the 12 months from the index surgery.  A participant was 
classified as having the primary clinical outcome if they experienced one or more of the 
following patient important outcomes: 1) re-operation, defined as any unplanned surgery 
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reported on any follow-up medical imaging study 3) severe femoral neck malunion, 
defined as shortening of >10mm in any plane on follow-up x-rays; or, 4) nonunion, 
defined as the failure of the fracture to progress towards healing defined as a 
Radiographic Union Score for Hip (RUSH) below 18, at 6 months or greater post-
injury.17 The individual complications within the composite outcome were chosen to 
balance a feasible one-year follow-up timeline and the likelihood of a clinically important 
event. For example, asymptomatic or “pre-collapse” femoral head osteonecrosis was 
included because many of these cases will not progress to full collapse or reoperation 
until more than 12-months post-injury.  
 
Secondary Clinical Outcomes 
The secondary outcomes for the pilot trial included fracture healing complications and 
radiographic fracture healing. Fracture healing complications included wound healing 
problems, infection (superficial and deep), hardware f ilure, hardware breakage, painful 
hardware, and peri-prosthetic fracture.  
 
Adjudication Procedures and Blinding 
An orthopaedic surgeon with prior adjudication experience independently adjudicated 
participant eligibility and study outcomes. Surgeons, research personnel, participants, and 
the adjudicator could not be blinded to the treatment allocation of the surgical 
interventions (SHS versus CS), but the data analyst, Steering Committee, and those 
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complete blinding of the supplement was achieved by using vitamin D3 and placebo 




The planned sample size for the definitive RCT was 898 patients. Based on our feasibility 
objectives for this pilot trial, we sought to enroll a minimum of 60 patients within a 12-
month recruitment period.  
 
Statistical Analysis of Outcomes 
We adopted the CONSORT extension to pilot trials in reporting the results of this pilot 
trial.18 The baseline characteristics, fracture and injury characteristics, surgical details, 
and peri-operative care data were summarized using descriptive statistics. We considered 
the clinical analyses of the pilot trial data as exploratory; therefore, we did not adjust for 
multiple testing, nor did the analyses seek to make definitive conclusions.19 The first 
analysis of clinical outcomes was a Cox proportional h zards regression with main 
effects for implant type and supplementation, and the interaction between the two. In this 
analysis, we used 377 days post-fracture as the time of censoring, which was the time of 
the last reported event within the composite, and within 2-weeks of the 12-month follow-
up date. We conducted additional sensitivity analyses censoring at 365 days, which did 
not change our study results. All analyses were adjusted for 1) femoral neck fracture 
displacement, 2) presence of an ipsilateral femoral shaft fracture, and 3) geographic 
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between the surgical implant and vitamin D supplement interventions was not significant, 
and therefore their treatment effects were analyzed separately. Hazard ratios with 95% 
confidence intervals (CI) were reported for each model. All outcome analyses adhered to 




Between February 2015 and March 2018, 91 patients were randomized from 15 North 
American hospitals into the FAITH-2 pilot trial. 86 patients were deemed eligible and 
included in the analyses (Figure 1 and Table, Supplemental Digital Content 1, 
http://links.lww.com/JOT/B21). Of the 86 participants, 43 were allocated to receive a 
sliding hip screw and 43 were allocated to receive CS. Concomitantly, 45 were allocated 
to receive vitamin D, and 41 were allocated to receive placebo (see Figure, 
Supplemental Digital Content 2, http://links.lww.com/JOT/B22). 12-month follow-up 
was achieved for 67 patients (77.9%). 
 
Participant Demographics and Fracture Characteristic  
Typical participants were men (73.3%) of white/Caucasian ethnicity (79.1%) with a mean 
age of 41.1 (SD 12.2). The majority of fractures were displaced (71%), with 44% of the 
fractures being a vertical Pauwels Type III pattern (Table 1). Of the 86 eligible 
participants, 15 (17.4%) also sustained an ipsilateral f moral shaft fracture (see Table, 
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Surgical Details 
The mean time from injury to surgery was similar acoss all treatment groups (median: 
21.2 hours, interquartile range: 18.1 hours). An open reduction was used in the majority 
of participants (55.8%).  The remainder of key surgical details are summarized in Table 
2.  
 
Vitamin D Supplementation Adherence 
The proportion of participants taking a minimum of 75% of their prescribed daily 
supplements decreased significantly with time. At 6 weeks post-fracture, 72.1% reported 
acceptable adherence; at 3-months the proportion decreased to 60.5%; at 6-months, only 
54.7% of participants were taking at least 75% of their daily doses. Overall, only 33% of 
participants reported full daily adherence for the first three months. 
 
Primary Clinical Outcome 
Eleven participants in the SHS group (25.6%) and 13 participants in the CS group 
(30.2%) experienced the composite complication outcome (HR 0.90, 95% CI 0.40 – 
2.02).  Re-operations accounted for nine SHS events and six CS events (Table 3). There 
were three conversions to total hip arthroplasty (THA) in the SHS group and one 
conversion to THA in the CS group (Table 4). There was one case in the SHS group and 
five cases in the CS group of femoral neck osteonecr sis that did not result in a re-
operation within the 12-month trial period. There was one case in the SHS group and two 
cases in the CS group of isolated femoral neck shortening >1 cm that was not also 
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were treated with a re-operation: four cases in the SHS group and three cases in the CS 
group.  
With respect to the vitamin D supplement comparison, the composite complication 
outcome occurred in 11 participants (24.4%) in the vitamin D group and 13 participants 
(31.7%) in the placebo group (HR 0.96, 95% CI 0.42 – 2.18).  There were seven 
reoperations in the vitamin D group and eight reoperations in the placebo group.  There 
were two conversions to THA in each treatment group.  Breakdowns of the primary 
clinical endpoint composite by treatment group and re-operation by treatment group are 
displayed in Tables 3 and 4, respectively. 
Secondary Clinical Outcomes 
Fracture Healing Complications 
All fracture healing complications were either treated with re-operation or captured under 
the primary composite outcome, except for one case. One participant in the CS surgical 
treatment group experienced painful hardware at the final 12-month follow-up visit that 
was not treated with re-operation. 
Ipsilateral Shaft Fractures 
Of the 86 eligible participants, 15 (17.4%) also sustained an ipsilateral femoral shaft 
fracture. The majority of these fractures were closed (64.7%) and located in the middle 
(76.5%) of the femoral shaft. Three participants in the CS group and none in the SHS 





Copyright  20 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.20
 18
We were able to confirm radiographic healing of the ipsilateral femoral shaft fracture in 
10 participants (66.7%). The average time to radiographic healing for ipsilateral femoral 
shaft fractures was 11.1 months (SD 3.8 months) for th se who did achieve radiographic 
healing and did not differ between the surgical treatment groups (p=0.75) nor the vitamin 
D supplementation treatment groups (p=0.52).  
 
DISCUSSION 
The FAITH-2 pilot trial successfully enrolled 86 young femoral neck fracture patients 
across 15 North American trauma centers. This pilot trial sought to demonstrate the 
feasibility of proceeding to a larger 898-patient definitive trial comparing the sliding hip 
screw (SHS) versus cancellous screws (CS) and supplementation with vitamin D3 versus 
placebo to independently reduce the risk of patient-important complications within 12-
months post-injury. Secondarily, the pilot trial sought to add to the sparse clinical 
outcomes data in this challenging fracture population. 
The slow recruitment and regulatory challenges of administering vitamin D outside of 
North America have led to the conclusion that the larger trial is not feasible. As expected, 
the preliminary clinical results do not approach stati ical significance within the pilot 
sample size; however, the point estimates for each treatment comparison are in the 
hypothesized direction. The hazard ratio for complications was 0.90 for the SHS relative 
to CS (p=0.80), and 0.96 for vitamin D supplementation relative to placebo (p=0.92).  
Despite the pilot nature, the clinical results of this trial are important exploratory 
comparisons. The previous literature comparing surgical implants for young femoral neck 
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reported CS led to decreased operative time, superior functional outcomes, and fewer 
complications; however, key data were missing from the report to support the author’s 
conclusions. Moreover, this trial was conducted in a developing country 30 years ago, 
and its generalizability to current practice remains u clear. These potential concerns have 
been further highlighted by conflicting retrospective studies suggesting superior 
outcomes with fixed angle devices.20,21 More recently, a fifty-eight patient RCT reported 
a larger proportion of CS patients lost >5°  of coronal alignment reduction within 6 
months of injury, and all were treated with a valgus intertrochanteric osteotomy (18% vs 
0%, p<0.001).22 There were no differences detected in the incidence of osteonecrosis, and 
the authors did not report the incidence of nonunion. 
With respect to our findings for the potential effectiveness of vitamin D supplementation, 
we are unaware of any previous results from other young femoral neck fracture 
populations. Even within other non-osteoporotic fracture populations, there have been 
few studies that have examined the effectiveness of vitamin D supplementation to 
improve fracture healing outcomes. Previous authors have shown that post-fracture 
vitamin D supplementation can increase serum 25(OH)D levels in the adult fracture 
population.23–25  Naturally, the increase in serum levels is dependent on patient 
adherence, which also seems to vary between populations. Andres et al. reported 82% of 
their adult fracture patients were adherent to a daily 1,600 IU vitamin D dose;25 this is 
much higher than the 33% of participants that reported taking their supplement daily in 
our trial.  Regardless, the evidence for the clinical effectiveness of vitamin D 
supplementation to reduce fracture complications remains lacking.26,27 Similarly, a recent 
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clinical indications.27 Despite the lack of efficacy data to suggest vitamin D 
supplementation improves fracture healing, some authors continue to recommend its 
routine use because it is an inexpensive intervention with a wide safety profile.28  
Our clinical results highlight ongoing uncertainty within surgical treatment and vitamin D 
supplement choices, and these results must be further considered within the limitations of 
the pilot trial. Since the sample size of the FAITH-2 pilot trial was chosen to test trial 
feasibility, it was underpowered to detect treatment effects and support definitive clinical 
comparisons. Despite this limitation, we decided to report the clinical results of FAITH-2 
as per the recommendation of Conn et al.29 Not only is it unethical to not report results of 
a conducted trial, but in making these results avail ble, it allows for their inclusion in 
future meta-analyses.29 Other challenges of the FAITH-2 pilot trial included relatively 
low participant adherence to taking the daily vitamin D supplement and maintaining 
>80% 1-year follow-up.16 This is not surprising compared to other hip fracture trials, 
given the higher proportion of young male participants and individuals with multiple 
injuries that were recruited.  Finally, it is important to recognize that the 1-year duration 
of follow-up may underestimate the occurrence of several important complications. For 
example, femoral head osteonecrosis is known to present later than 1-year post-injury, 
and population-level data suggest the median time to conversion to total hip arthroplasty 
after a young femoral neck fracture is 16 months.30   
Despite the inability of this pilot data to guide strong clinical recommendations, the 
FAITH-2 trial is an incremental step towards improving clinical research within this 
challenging fracture population. The 2x2 factorial r ndomization allowed for novel 
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trial.  The multi-center recruitment helped increase the sample size and ensure the results 
are generalizable beyond a single center. The vitamin D intervention was placebo 
controlled and double-blinded, which removes multiple otential sources of treatment and 
assessment biases. Although the surgical interventions could not be blinded, a single 
independent orthopaedic surgeon adjudicated all tri outcomes to minimize any local site 
or investigator biases. 
There are several important over-arching conclusions to be drawn from the FAITH-2 
trial. First, the complication rate of internal fixation for young femoral neck fractures 
remains >20%. Second, despite the apparent need to impr ve treatment outcomes, it is 
unlikely to be feasible to conduct a large multi-center trial in this fracture population. 
Third, the superiority of a surgical implant to decrease the risk of nonunion remains to be 
proven in both young and elderly femoral neck fractures; however, the complication 
profile of the SHS and CS continues to be consistent.  It was the implant specific 
complications that were the primary determinant of differences in the risk for reoperation 
among the displaced elderly femoral neck fractures in the FAITH trial (HR 0.57, p=0.04). 
CS fail with varus fracture collapse and lateral screw prominence; the SHS fails with 
superior screw cutout.  Therefore, the relevant clinical question may not be, “Which 
implant is better?” but rather, “Which complication profile is most acceptable for each 
individual patient?” Finally, when considering whether to add vitamin D supplementation 
to the post-operative treatments of young femoral neck fracture patients, surgeons should 
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The FAITH-2 program will not proceed to a definitive trial, but these pilot trial results 
continue to describe the results of current fixation mplants, inform the challenges of 
improving outcomes in this fracture population, and may guide future vitamin D trials to 
improve healing outcomes in young fracture populations. Although the pilot trial was not 
adequately powered to detect treatment effects, publishing these results may facilitate 
future meta-analyses on this topic.  
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Age in years, mean (SD) 39.2 (13.2) 43.0 (11.4) 40.6 (12.0) 41.6 (13.0) 41.1 (12.4) 













Ethnicity, n (%) 
 Native/Aboriginal 
 South Asian 
 East Asian 
 Southeast Asian (Filipino) 
 Hispanic/Latino 
 White/Caucasian 
 Black (African/Caribbean) 
 Mixed (Black & White) 














































Work Related Injury, n (%) 4 (9.3) 8 (18.6) 8 (17.8) 4 (26.7) 12 (14.1) 
History of Smoking, n (%) 
 Yes 























Consumption of Alcohol, n (%) 29 (67.4) 24 (55.8) 32 (71.1) 21 (51.2) 53 (61.6) 
Current Medications, n (%) 
 None 
 NSAID 
 Steroid Medications 
 Calcium 
























































































Garden Classification, n (%) 
 Garden I (undisplaced) 
 Garden II (undisplaced) 
 Garden III (displaced) 
 Garden IV (displaced) 


























Pauwels’ Classification, n (%) 
 Type I 
 Type II 
 Type III 
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Time from Injury to Surgery in hours, mean (SD) 28.9 (24.3) 25.0 
(16.2) 
28.0 (23.4) 25.7 (17.5) 26.9 (20.6) 
Type of Reduction Used, n (%) 
  Closed 
  Open 





















Procedure Performed, n (%) 
  CS 
  SHS 





















Other Procedures Performed During Same 
Operation as Femoral Neck Fracture Internal 
Fixation, n (%) 
14 (32.6) 11 (25.6) 14 (31.1) 11 (26.8) 25 (29.1) 
Number of Screws Used, n (%) 
   Three 




    
Diameter of Screws, n (%) 
   6.5 mm 
   7.3 mm 





    
Formation of Screws (or Pins), n (%) 
   Triangle (Apex at Top) (3 Screws) 
   Inverted Triangle (Apex at Bottom) (3 Screws) 
   Square (4 Screws) 
   Diamond 







    
Aiming of Screws (or Pins), n (%) 
   Parallel 




    
Type of Sliding Fixed-Angle Plate Construct 
Used, n (%) 
   Traditional Large Diameter Hip Screw     








   
Implant Position in Head of Femur  
   Centre-Centre Position, n (%) 
   Superior Position 
   Anterior Position  
   Inferior Position  









   
Supplemental (Derotational) Screws Included in 
Fixation, n (%)  
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Primary Clinical Endpoint*, n (%)  24 (27.9) 13 (30.2) 11 (25.6) 11 (24.4) 13 (31.7) 
  
Individual Endpoints  
Re-operation,** n (%) 15 (17.4) 6 (14.0) 9 (20.9) 7 (15.2) 8 (19.5) 
Femoral head osteonecrosis,***  n (%) 9 (10.5) 7 (16.3) 2 (4.7) 5 (10.9) 4 (10.0) 
Severe femoral neck malunion,****  n (%) 8 (9.3) 6 (14.0) 2 (4.7) 5 (10.9) 3 (7.5) 
Nonunion,*****  n (%) 7 (8.2) 3 (7.0) 4 (9.3) 4 (8.7) 3 (7.5) 
*For the primary clinical endpoint, one event per patient was counted  
**3 patients underwent two, two, and three separate re-operations, respectively. Therefore, breakdown f re-
operations totals to 19 instead of 15.  
***3 patients with femoral head osteonecrosis also underwent a re-operation 
****3 patients with severe femoral neck malunion also underwent a re-operation, 2 patients with severe femoral 
neck malunion also had femoral head osteonecrosis, and 1 patient with severe femoral neck malunion had a 
nonunion 
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Primary Clinical Endpoint of Re-operation   
 
Re-operation*, n (%) 15 (17.4) 6 (14.0) 9 (20.9) 7 (15.2) 8 (19.5) 
 
Conversation to Total Hip Arthroplasty, n 
(%) 
4 (4.7) 1 (2.3) 3 (7.0) 2 (4.4) 2 (4.9) 
 
Proximal Femur Osteotomy, n (%) 5 (5.8) 3 (7.0) 2 (4.7) 3 (6.7) 2 (4.9) 
 
Implant Removal, n (%) 5 (5.8) 1 (2.3) 4 (9.3) 1 (2.2) 4 (10.0) 
 
Irrigation and Debridement for Deep 
Infection, n (%) 
3 (3.5) 0 (0.0) 3 (7.0) 3 (6.7) 0 (0.0) 
 
Implant Exchange, n (%) 2 (2.3) 1 (2.3) 1 (2.3) 0 (0.0) 2 (4.9) 
 
*For the primary clinical endpoint, one event per patient was counted  
*3 patients underwent two, two, and three separate re-operations, respectively. Therefore, breakdown of re-
operations totals to 19 instead of 15.  
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Allocated to SHS (N=46) Allocated to CS (N=45)
Randomization Errors (N=3)
2 did not provide informed consent   
1 did not have a femoral neck fracture
Randomization Errors (N=2)
1 not between the ages of 18-60 years 
1 pathological fracture
Included in primary analysis (N=43) Included in primary analysis (N=43)
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